Other
CN
EU
USA
Description: Risperidone (R-64766; R64766 and Risperdal), an marketed atypical antipsychotic, is a potent mutil-targeted antagonist for dopamine, serotonin, adrenergic and histamine receptors, it has been approved for use in the treatment of schizophrenia and bipolar disorder. Risperidone binds to both DA and serotonin (5HT) receptors, particularly in the neurons of striatal and limbic structures. Risperidone significantly affects brain nerve growth factor (NGF) level suggesting that it influences the turnover of endogenous growth factors.
References: J Neurosci Res. 2000 Jun 15;60(6):783-94; Brain Res. 2002 Dec 6;957(1):144-51.
Related CAS #: 666179-96-0 (mesylate); 106266-06-2 (free base)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
In vitro activity: Risperidone binds to both DA and serotonin (5HT) receptors, particularly in the neurons of striatal and limbic structures. Risperidone significantly affects brain nerve growth factor (NGF) level suggesting that it influences the turnover of endogenous growth factors. Risperidone significantly decreases BDNF concentrations in frontal cortex, occipital cortex and hippocampus and decreases or increases TrkB receptors in selected brain structures. Risperidone significantly increases D(2) binding in medial prefrontal cortex by 34% in rat forebrain regions. Risperidone produces even greater up-regulation of D(4) receptors in CPu (37%), NAc (32%), and HIP (37%) in rat forebrain regions. Risperidone significantly inhibits the production of NO and proinflammatory cytokines by activated microglia. Risperidone (1-50 mM) significantly enhances the intracellular accumulation of Rh123 in Caco-2 cells by inhibiting P-gp activity with an IC(50) value of 5.87 mM.
J Neurosci Res. 2000 Jun 15;60(6):783-94; Brain Res. 2002 Dec 6;957(1):144-51.
Purity ≥98%
COA
MSDS